Cordlife GroupCLIFF 42 10-Year ROIIC % is 12.66 as of Dec. 2025. GuruFocus rates CLIFF with a GF Score™ of 42/100 and a GF Value™ of $0.08 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 178 Medical Diagnostics & Research companies, Cordlife Group ranks better than 73.03% on this metric.
10-Year Return on Invested Incremental Capital (10-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 10-year.
Cordlife Group's 10-Year ROIIC % for the quarter that ended in Dec. 2025 was 12.66%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Cordlife Group's 10-Year ROIIC % or its related term are showing as below:
CLIFF's 10-Year ROIIC % is ranked better than 73.03% of 178
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.52
vs CLIFF: 12.66
Cordlife Group (OTCPK:CLIFF) 10-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Cordlife Group 10-Year ROIIC % Related Terms
Cordlife Group 10-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Cordlife Group's 10-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CLIFF vs TMO, DHR, IDXX: 10-Year ROIIC % Comparison
For the Diagnostics & Research subindustry, Cordlife Group's 10-Year ROIIC %, along with its competitors' market caps and 10-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cordlife Group 10-Year ROIIC % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Cordlife Group's 10-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Cordlife Group's 10-Year ROIIC % falls into.
Cordlife Group's 10-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
10-Year ROIIC %
=
10-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
10-Year Incremental Invested Capital**
=
( -11.496 (Dec. 2025) - 3.9284676 (Jun. 2015) )
/
( 105.93 (Dec. 2025) - 219.73 (Jun. 2015) )
=
-15.4244676
/
-113.8
=
13.55%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 10-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Cordlife Group (CLIFF) has a 10-Year ROIIC % of 12.66 as of Dec. 2025. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on Cordlife Group and its competitors. According to the industry distribution chart, Cordlife Group ranks #48 out of 178 companies in the Medical Diagnostics & Research industry, placing it in the top 27%.
Is Cordlife Group's 10-Year ROIIC % too high?
Cordlife Group's current 10-Year ROIIC % is 12.66. The Medical Diagnostics & Research industry median 10-Year ROIIC % is 1.52. Cordlife Group's value of 12.66 is 732.9% above this industry median. Based on the distribution chart, Cordlife Group ranks #48 out of 178 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Cordlife Group has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cordlife Group's 10-Year ROIIC % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Cordlife Group ranks #48 out of 178 companies for 10-Year ROIIC %. This puts Cordlife Group in the upper half of its industry. The industry median 10-Year ROIIC % is 1.52. Cordlife Group's value of 12.66 is 732.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year ROIIC % for a Medical Diagnostics & Research company?
The median 10-Year ROIIC % among Medical Diagnostics & Research companies is 1.52, based on 178 companies in the industry. Companies in the top quartile (top 25%) have a 10-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 10-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cordlife Group's current 10-Year ROIIC % of 12.66 is 732.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year ROIIC % mean?
A high 10-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on Cordlife Group and its competitors. For the Medical Diagnostics & Research industry, the median 10-Year ROIIC % is 1.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cordlife Group's current 10-Year ROIIC % is 12.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cordlife Group stock overvalued right now?
Based on GuruFocus' analysis, Cordlife Group (CLIFF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.08, compared to a current price of $0.15 — trading 88.1% above its estimated fair value. The current 10-Year ROIIC % is 12.66 and 732.9% above the Medical Diagnostics & Research industry median of 1.52. Cordlife Group's overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year ROIIC % calculated?
10-Year ROIIC % is calculated from a company's financial statements. For Cordlife Group (CLIFF), the current 10-Year ROIIC % is 12.66 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cordlife Group (CLIFF) Overvalued in 2026?
Based on GuruFocus' analysis, Cordlife Group stock appears to be overvalued.
The current stock price of $0.15 is trading 88.1% above its estimated GF Value™ of $0.08.
GuruFocus considers Cordlife Group to be Significantly Overvalued.
Key valuation signals for CLIFF:
10-Year ROIIC %: 12.66
GF Value™: $0.08 vs. price of $0.15 (88.1% above fair value)
Industry Position: 732.9% above the Medical Diagnostics & Research median (#48 of 178)
No single metric tells the full story. See the CLIFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cordlife Group Ltd is a consumer healthcare company dedicated to safeguarding the well-being of mother and child. Along with its subsidiaries, the company is engaged in the provision of diagnostics and cord blood banking services, which involve the processing and storage of cord blood stem cells. The group has two reportable segments as follows: the Banking segment, which derives maximum revenue, comprises the collection, processing, and banking of biological materials; and the Diagnostics segment, which comprises diagnostics testing services. Geographically, the group generates maximum revenue from Hong Kong, and the rest from the Philippines, India, Malaysia, Singapore, and other regions.
42GF Score
Get the complete analysis for CLIFF
10-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLIFF has been successfully added to your 
